SynerFuse

Executive Summary

SynerFuse is a Minneapolis-based medical device company founded in 2019, focused on addressing the unmet need in chronic low back and leg pain through its innovative e-TLIF procedure. This patented approach combines spinal fusion surgery with direct nerve stimulation at the same spinal level, delivering Ultra Low Energy (ULE) therapy specifically targeting neuropathic pain that is often unaddressed by traditional fusion surgery. The company’s core technology, the NeuroFuse System, aims to provide a comprehensive solution for patients suffering from persistent pain after fusion, potentially reducing opioid dependence and improving clinical outcomes. By integrating stimulation into the fusion construct, SynerFuse offers a novel therapeutic pathway that could disrupt the standard of care for lumbar spine disorders. Despite being in the early stages of commercialization, SynerFuse has established a strong intellectual property position and is likely advancing toward clinical validation. The company has not disclosed funding rounds or revenue, but its focus on a high-volume spine market (over 500,000 fusion procedures annually in the U.S.) suggests significant commercial potential. Key near-term milestones include the initiation of pivotal clinical trials, regulatory submissions (FDA 510(k) or IDE approval), and strategic partnerships with spine implant manufacturers. If successful, SynerFuse could become a leading platform for combined fusion and neuromodulation, capturing a share of the multi-billion-dollar spine surgery market. Conviction is moderate, given the early-stage nature and execution risks inherent in medical device development.

Upcoming Catalysts (preview)

• Q4 2026FDA IDE Approval for Pivotal Clinical Trial of NeuroFuse System65% success
• Q2 2027First-In-Human Results from Pilot Study60% success
• TBDStrategic Partnership with Major Spine Device Company40% success